7 August 2017: ReNeuron Group plc (“the Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2017 and the Notice of the 2017 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.

Read more…

The Annual Report and Accounts can be found under the Investors section or by clicking here.

25 July 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Nplus1 Singer Advisory LLP as joint broker to the Company with immediate effect.

Read more…

19 July 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that Dr Paul Harper, a non-executive director of the business since the Company’s flotation on AIM in 2005, will step down from the Board at the next Annual General Meeting of the Company.

Read more…

29 June 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2017.

Read more…

To view the webcast of the 2017 preliminary results presentation click here..

19 June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on its cell therapy development programmes targeting degenerative diseases of the retina.

Read more…

8th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2017 on Thursday 29 June 2017.

Read more..

 

 

5th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a further update regarding its US clinical and regulatory development strategy for its CTX cell therapy candidate for stroke disability.

Read more…

18th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at a leading scientific conference.

Read more…

11th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has been awarded a £1.8 million grant from Innovate UK to further advance its next generation commercial cell therapy manufacturing capabilities.

Read more..

5th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will today be presenting new data relating to the characterisation and scale-up of its CTX cell-derived exosome therapy candidates at a leading scientific conference in London.

Read more…